KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other financing activities (2018 - 2025)

Historic Other financing activities for Rigel Pharmaceuticals (RIGL) over the last 10 years, with Q3 2025 value amounting to $4.3 million.

  • Rigel Pharmaceuticals' Other financing activities rose 260316.46% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 57390.86%. This contributed to the annual value of $2.0 million for FY2024, which is 8722.59% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Other financing activities stood at $4.3 million, which was up 260316.46% from $418000.0 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Other financing activities ranged from a high of $4.3 million in Q3 2025 and a low of $1000.0 during Q1 2023
  • In the last 5 years, Rigel Pharmaceuticals' Other financing activities had a median value of $486000.0 in 2023 and averaged $852941.2.
  • In the last 5 years, Rigel Pharmaceuticals' Other financing activities tumbled by 9989.36% in 2023 and then surged by 880000.0% in 2024.
  • Rigel Pharmaceuticals' Other financing activities (Quarter) stood at $1.1 million in 2021, then tumbled by 44.79% to $599000.0 in 2022, then dropped by 18.86% to $486000.0 in 2023, then skyrocketed by 201.44% to $1.5 million in 2024, then surged by 191.54% to $4.3 million in 2025.
  • Its Other financing activities was $4.3 million in Q3 2025, compared to $418000.0 in Q2 2025 and $484000.0 in Q1 2025.